Something remarkable happened in crypto last year. It wasn’t another price rally or NFT frenzy; people started spending… The post Visa-issured crypto cards surgeSomething remarkable happened in crypto last year. It wasn’t another price rally or NFT frenzy; people started spending… The post Visa-issured crypto cards surge

Visa-issured crypto cards surge 525% in 2025 as real world crypto spending hits Main Street

2026/01/05 23:02
3 min read

Something remarkable happened in crypto last year. It wasn’t another price rally or NFT frenzy; people started spending their cryptocurrency in the real world like never before. Visa-backed crypto cards saw net spending explode by 525% in 2025. Data from Dune Analytics shows the total jumped from $14.6 million in January to $91.3 million by December.

This wasn’t trading volume or wallet inflows, but actual purchases at merchants, processed over Visa’s global network. Six innovative cards drove the growth, all issued through partnerships between blockchain projects and Visa. The lineup included Gnosis Pay, Cypher, EtherFi, Avici Money, Exa App, and Moonwell.

EtherFi dominated with $55.4 million in annual spend. Cypher followed closely at $20.5 million. Together, they accounted for most of the surge. These aren’t centralised exchange cards. They’re tied to decentralised finance protocols, letting users spend stablecoins and on-chain assets directly.

Visa-issured crypto cards surge 525% in 2025 as real world crypto spending hits Main StreetVisa-issured crypto cards

The trend highlights a shift. Crypto holders increasingly want utility, not just speculation. Stablecoins fuelled most transactions, offering stability and seamless conversion to fiat at the point of sale.

Crypto card spending surge signals a bigger shift in payments

Polygon researcher Alex Obchakevich, who built the Dune dashboard, shared, X: “These figures demonstrate not only the fast adoption of crypto cards among users but also the strategic importance of crypto and stablecoins for Visa’s global payment ecosystem.”

He added that the rising spend proves crypto has evolved into a “fully-fledged tool for everyday financial transactions.”

Visa leaned in hard, expanding stablecoin support across four blockchains. In mid-December, it launched a dedicated advisory team to guide banks, merchants, and fintechs on stablecoin integration.

For DeFi projects, these cards are game-changers. They turn idle token balances into active spending, earning interchange fees while boosting user loyalty. Gnosis Pay offers self-custodial control. EtherFi ties spending to liquid staking rewards. The result? Holders spend without selling assets.

Visa-issured crypto cards surge 525% in 2025 as real world crypto spending hits Main Street

Merchants benefit too. Crypto cards reduce cross-border friction and open new customer segments. In emerging markets, they bypass volatile local currencies. Globally, they appeal to younger users who prefer token rewards over cashback.

The sample covers only six cards, so total market volume is likely higher. Still, the trajectory stands out. Larger players have bigger numbers, but these DeFi-native cards grew fastest, showing innovation at the edges.

Read also: Africa missing as Singapore tops global crypto usability index in 2025

2025 proved crypto can power everyday commerce. With Visa’s infrastructure bridging the gap, on-chain assets are moving from wallets to checkout counters. 2026 could see even broader adoption as more projects launch similar products. The payments landscape just got more interesting.

The post Visa-issured crypto cards surge 525% in 2025 as real world crypto spending hits Main Street first appeared on Technext.

Market Opportunity
Collector Crypt Logo
Collector Crypt Price(CARDS)
$0.03986
$0.03986$0.03986
-7.49%
USD
Collector Crypt (CARDS) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26